Cargando…

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.

Detalles Bibliográficos
Autores principales:	Pérez-Pinilla, Belén, Bonis-Braun, Carolina De, Saavedra, Minerva Montalvo, Diaz-Lopez, Marta, González-Casanova, Paula Reyes, Salazar, María José Rodríguez, Machado-Machado, Patricia, Raya, Jose Maria, Garcia, Miguel Teodoro Hernandez, Lakhwani, Sunil Lakhwani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428757/ http://dx.doi.org/10.1097/01.HS9.0000976012.99908.9d

Ejemplares similares

PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Lakhwani, Sunil Lakhwani, et al.
Publicado: (2023)

PB2210: COMPARISON OF THREE PROGNOSTIC SCORING SYSTEMS FOR THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: ANALYSIS OF 190 PATIENTS AT THE UNIVERSITY HOSPITAL OF THE CANARY ISLANDS (1990-2022)
por: Raya, Jose Maria, et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

PB2323: ACQUIRED HEMOPHILIA: A CASE REPORT
por: Haddad, N., et al.
Publicado: (2022)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

Severe hypomagnesaemia with tetany following ESHAP protocol
por: Majumdar, Gautam
Publicado: (2002)

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Boonlerd, Pattamaporn, et al.
Publicado: (2023)

Intramuscular Anti‐D treatment for immune thrombocytopenia: A single centre experience
por: Lakhwani, Sunil, et al.
Publicado: (2022)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

2323. Unexpected Pediatric Presentation Patterns of Toxic Shock Syndrome
por: Spaeth-Cook, Aliza, et al.
Publicado: (2018)

Correlation of Trochanter-Shaft Angle in Selection of Entry Site in Antegrade Intramedullary Femoral Nail
por: Lakhwani, O. P.
Publicado: (2012)

Percutaneous Method of Management of Simple Bone Cyst
por: Lakhwani, O. P.
Publicado: (2013)

PB2530: DIXON-BASED R2* MRI AS AN INTEGRATION/SUBSTITUTE OF STANDARD T2*/R2* IN THE EVALUATION OF IRON OVERLOAD IN THE UPPER ABDOMEN
por: Pinto, Valeria Maria, et al.
Publicado: (2023)

Analysis of the Rdr1 gene family in different Rosaceae genomes reveals an origin of an R-gene cluster after the split of Rubeae within the Rosoideae subfamily
por: Menz, Ina, et al.
Publicado: (2020)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
por: Hamadani, M., et al.
Publicado: (2022)

Active waveguide Bragg lasers via conformal contact PDMS stamps
por: Li, Yun, et al.
Publicado: (2022)

PReS-FINAL-2323: Cryoglobulinemic vasculitis preceding diagnosis of Carney complex
por: Glerup, MB, et al.
Publicado: (2013)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
por: Ramzi, Mani, et al.
Publicado: (2015)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
por: Nukariya, Hironao, et al.
Publicado: (2023)

PB2498: A PHASE 1 STUDY OF WU-NK-101 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Cashen, Amanda, et al.
Publicado: (2023)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE
por: Antipova, A., et al.
Publicado: (2022)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

Whole-Exome Sequencing Identifies Somatic Mutations Associated With Mortality in Metastatic Clear Cell Kidney Carcinoma
por: Mendoza-Alvarez, Alejandro, et al.
Publicado: (2019)

Debilitating Fracture Hampering the Regular Chores of an 80-Year-Old Female and the Post-operative Rehabilitation for the Same: A Case Report
por: Raipure, Anushka, et al.
Publicado: (2022)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Correction: GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
por: Ramzi, Mani, et al.
Publicado: (2015)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

Undiagnosed Bilateral Avascular Necrosis of the Femur in a Young Male Caused by COVID-19 Steroid Injections
por: Kamani, Sakshi, et al.
Publicado: (2022)

PB2590: BREAKTHROUGH INVASIVE FUNGAL INFECTION CAUSED BY SCEDOSPORIUM APIOSPERMUM IN PEDIATRIC PATIENT WITH ACUTE MYELOID LEUKEMIA: DIAGNOSTIC, CLINICAL COURSE AND TREATMENT
por: Raya, María Pérez, et al.
Publicado: (2023)

PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
por: Lee, E., et al.
Publicado: (2022)

Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin’s lymphoma: a case report
por: Elazzazy, Shereen, et al.
Publicado: (2013)

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases
por: Ungur, Rodica, et al.
Publicado: (2015)

Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gc874m63tqirt57mc6b3h44tgb